Daiken Biomedical (7780) 주식 개요다이켄 바이오메디컬은 건강 식품의 연구 및 개발에 종사하는 기업입니다. 자세히 보기7780 펀더멘털 분석스노우플레이크 점수가치 평가2/6미래 성장0/6과거 실적2/6재무 건전성5/6배당1/6강점공정 가치 추정치보다 낮은 28% 에서 거래지난 1년간 수익이 39% 증가했습니다.위험 분석높은 수준의 비현금 수입3.81%의 배당금은 수익이나 자유현금흐름으로 잘 충당되지 않습니다.지난 1년 동안 주주가 크게 희석되었습니다.모든 위험 점검 보기7780 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW494,503 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINROAG494,503 investors already sharing narrativesYour Fair ValueNT$Current PriceNT$18.35382.9% 고평가 내재 할인율Growth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture02b2016201920222025202620282031Revenue NT$2.0bEarnings NT$337.2mAdvancedSet Fair ValueView all narrativesDaiken Biomedical Co., Ltd. 경쟁사Grape King BioSymbol: TWSE:1707Market cap: NT$13.8bTCISymbol: TPEX:8436Market cap: NT$12.7bChlitina HoldingSymbol: TWSE:4137Market cap: NT$8.0bDr. Wu SkincareSymbol: TPEX:6523Market cap: NT$4.2b가격 이력 및 성과Daiken Biomedical 주가의 최고가, 최저가 및 변동 요약과거 주가현재 주가NT$18.3552주 최고가NT$40.1052주 최저가NT$16.00베타01개월 변동2.80%3개월 변동-17.53%1년 변동-22.57%3년 변동n/a5년 변동n/aIPO 이후 변동3.09%최근 뉴스 및 업데이트Upcoming Dividend • Jun 15Upcoming dividend of NT$0.89 per shareEligible shareholders must have bought the stock before 22 June 2026. Payment date: 08 July 2026. The company is paying out more than 100% of its earnings and cash flow. Trailing yield: 3.6%. Lower than top quartile of Taiwanese dividend payers (4.9%). Lower than average of industry peers (5.8%).New Risk • May 09New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 40% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risks Dividend is not well covered by earnings and cash flows. Payout ratio: 115% Cash payout ratio: 191% High level of non-cash earnings (40% accrual ratio). Shareholders have been substantially diluted in the past year (35% increase in shares outstanding).Buy Or Sell Opportunity • Mar 31Now 20% undervaluedOver the last 90 days, the stock has risen 11% to NT$20.00. The fair value is estimated to be NT$25.02, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 24% over the last 3 years. Earnings per share has declined by 14%.Valuation Update With 7 Day Price Move • Mar 27Investor sentiment improves as stock rises 15%After last week's 15% share price gain to NT$22.00, the stock trades at a trailing P/E ratio of 52.7x. Average forward P/E is 19x in the Personal Products industry in Taiwan. Total returns to shareholders of 24% over the past year.Buy Or Sell Opportunity • Mar 16Now 21% undervaluedOver the last 90 days, the stock has risen 20% to NT$19.30. The fair value is estimated to be NT$24.32, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 24% over the last 3 years. Earnings per share has declined by 13%.New Risk • Mar 11New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 31% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (10% average weekly change). Dividend is not well covered by earnings and cash flows. Payout ratio: 218% Cash payout ratio: 122% High level of non-cash earnings (31% accrual ratio). Shareholders have been substantially diluted in the past year (35% increase in shares outstanding).더 많은 업데이트 보기Recent updatesUpcoming Dividend • Jun 15Upcoming dividend of NT$0.89 per shareEligible shareholders must have bought the stock before 22 June 2026. Payment date: 08 July 2026. The company is paying out more than 100% of its earnings and cash flow. Trailing yield: 3.6%. Lower than top quartile of Taiwanese dividend payers (4.9%). Lower than average of industry peers (5.8%).New Risk • May 09New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 40% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risks Dividend is not well covered by earnings and cash flows. Payout ratio: 115% Cash payout ratio: 191% High level of non-cash earnings (40% accrual ratio). Shareholders have been substantially diluted in the past year (35% increase in shares outstanding).Buy Or Sell Opportunity • Mar 31Now 20% undervaluedOver the last 90 days, the stock has risen 11% to NT$20.00. The fair value is estimated to be NT$25.02, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 24% over the last 3 years. Earnings per share has declined by 14%.Valuation Update With 7 Day Price Move • Mar 27Investor sentiment improves as stock rises 15%After last week's 15% share price gain to NT$22.00, the stock trades at a trailing P/E ratio of 52.7x. Average forward P/E is 19x in the Personal Products industry in Taiwan. Total returns to shareholders of 24% over the past year.Buy Or Sell Opportunity • Mar 16Now 21% undervaluedOver the last 90 days, the stock has risen 20% to NT$19.30. The fair value is estimated to be NT$24.32, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 24% over the last 3 years. Earnings per share has declined by 13%.New Risk • Mar 11New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 31% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (10% average weekly change). Dividend is not well covered by earnings and cash flows. Payout ratio: 218% Cash payout ratio: 122% High level of non-cash earnings (31% accrual ratio). Shareholders have been substantially diluted in the past year (35% increase in shares outstanding).Reported Earnings • Mar 11Full year 2025 earnings released: EPS: NT$0.51 (vs NT$0.24 in FY 2024)Full year 2025 results: EPS: NT$0.51 (up from NT$0.24 in FY 2024). Revenue: NT$1.90b (up 39% from FY 2024). Net income: NT$337.9m (up 217% from FY 2024). Profit margin: 18% (up from 7.8% in FY 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 34% p.a. on average during the next 2 years, compared to a 9.4% growth forecast for the Personal Products industry in Asia.공시 • Mar 10Daiken Biomedical Co., Ltd., Annual General Meeting, Jun 04, 2026Daiken Biomedical Co., Ltd., Annual General Meeting, Jun 04, 2026, at 09:00 Taipei Standard Time. Location: 4 floor building. a no,187, chin hua st., da-an district, taipei city TaiwanValuation Update With 7 Day Price Move • Mar 09Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to NT$20.40, the stock trades at a trailing P/E ratio of 61.5x. Average forward P/E is 19x in the Personal Products industry in Taiwan. Total returns to shareholders of 20% over the past year.Buy Or Sell Opportunity • Jan 27Now 24% undervaluedOver the last 90 days, the stock has risen 56% to NT$26.05. The fair value is estimated to be NT$34.11, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 23% over the last 3 years. Earnings per share has declined by 20%.Valuation Update With 7 Day Price Move • Jan 27Investor sentiment improves as stock rises 17%After last week's 17% share price gain to NT$26.05, the stock trades at a trailing P/E ratio of 78.6x. Average forward P/E is 22x in the Personal Products industry in Taiwan. Total returns to shareholders of 51% over the past year.New Risk • Jan 16New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Dividend is not well covered by earnings and cash flows. Payout ratio: 218% Cash payout ratio: 112% Shareholders have been substantially diluted in the past year (35% increase in shares outstanding). Minor Risk Share price has been volatile over the past 3 months (6.5% average weekly change).New Risk • Nov 26New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 35% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Dividend is not well covered by earnings and cash flows. Payout ratio: 218% Cash payout ratio: 152% Shareholders have been substantially diluted in the past year (35% increase in shares outstanding).Upcoming Dividend • Nov 17Upcoming dividend of NT$1.70 per shareEligible shareholders must have bought the stock before 24 November 2025. Payment date: 30 December 2025. Payout ratio is a comfortable 75% and the cash payout ratio is 83%. Trailing yield: 2.2%. Lower than top quartile of Taiwanese dividend payers (5.4%). Lower than average of industry peers (5.6%).Reported Earnings • Nov 08Third quarter 2025 earnings released: EPS: NT$1.06 (vs NT$0.80 in 3Q 2024)Third quarter 2025 results: EPS: NT$1.06 (up from NT$0.80 in 3Q 2024). Revenue: NT$449.3m (up 53% from 3Q 2024). Net income: NT$69.4m (up 45% from 3Q 2024). Profit margin: 16% (in line with 3Q 2024). Revenue is forecast to grow 34% p.a. on average during the next 3 years, compared to a 9.5% growth forecast for the Personal Products industry in Asia.Buy Or Sell Opportunity • Oct 03Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 21% to NT$188. The fair value is estimated to be NT$239, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 32% over the last year. Earnings per share has declined by 9.8%.Valuation Update With 7 Day Price Move • Sep 09Investor sentiment deteriorates as stock falls 28%After last week's 28% share price decline to NT$219, the stock trades at a trailing P/E ratio of 53.2x. Average trailing P/E is 17x in the Personal Products industry in Taiwan.공시 • Aug 21Daiken Biomedical Co., Ltd. has filed a Follow-on Equity Offering.Daiken Biomedical Co., Ltd. has filed a Follow-on Equity Offering. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 6,615,000 Price\Range: TWD 158 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 1,512,000 Price(minimum): TWD 147.66Upcoming Dividend • Aug 18Upcoming dividend of NT$2.45 per shareEligible shareholders must have bought the stock before 25 August 2025. Payment date: 15 September 2025. Payout ratio is on the higher end at 97%, and the cash payout ratio is above 100%. Trailing yield: 1.2%. Lower than top quartile of Taiwanese dividend payers (5.3%). Lower than average of industry peers (4.6%).Reported Earnings • Aug 15Second quarter 2025 earnings released: EPS: NT$0.65 (vs NT$1.05 in 2Q 2024)Second quarter 2025 results: EPS: NT$0.65. Revenue: NT$454.9m (up 61% from 2Q 2024). Net income: NT$38.8m (up 13% from 2Q 2024). Profit margin: 8.5% (down from 12% in 2Q 2024). The decrease in margin was driven by higher expenses.Valuation Update With 7 Day Price Move • Jul 16Investor sentiment improves as stock rises 39%After last week's 39% share price gain to NT$319, the stock trades at a trailing P/E ratio of 78.8x. Average trailing P/E is 17x in the Personal Products industry in Taiwan.Upcoming Dividend • Jul 15Upcoming dividend of NT$2.19 per shareEligible shareholders must have bought the stock before 22 July 2025. Payment date: 15 August 2025. The company is paying out more than 100% of its earnings and cash flow. Trailing yield: 1.2%. Lower than top quartile of Taiwanese dividend payers (5.3%). Lower than average of industry peers (4.7%).New Risk • Jul 09New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 7.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (42% accrual ratio). Minor Risk Share price has been volatile over the past 3 months (7.7% average weekly change).Valuation Update With 7 Day Price Move • Jul 02Investor sentiment improves as stock rises 23%After last week's 23% share price gain to NT$221, the stock trades at a trailing P/E ratio of 54.7x. Average trailing P/E is 17x in the Personal Products industry in Taiwan.Upcoming Dividend • Jun 10Upcoming dividend of NT$3.32 per shareEligible shareholders must have bought the stock before 17 June 2025. Payment date: 04 July 2025. The company is paying out more than 100% of its earnings and cash flow. Trailing yield: 2.3%. Lower than top quartile of Taiwanese dividend payers (5.2%). Lower than average of industry peers (5.2%).Reported Earnings • Apr 25Full year 2024 earnings released: EPS: NT$2.43 (vs NT$10.32 in FY 2023)Full year 2024 results: EPS: NT$2.43 (down from NT$10.32 in FY 2023). Revenue: NT$1.36b (up 14% from FY 2023). Net income: NT$106.6m (down 34% from FY 2023). Profit margin: 7.8% (down from 14% in FY 2023). The decrease in margin was driven by higher expenses.New Risk • Apr 14New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (25% accrual ratio). Minor Risk Latest financial reports are more than 6 months old (reported June 2024 fiscal period end).공시 • Mar 08Daiken Biomedical Co., Ltd., Annual General Meeting, Jun 10, 2025Daiken Biomedical Co., Ltd., Annual General Meeting, Jun 10, 2025. Location: 4 floor building. a no,187, chin hua st., da-an district, taipei city Taiwan주주 수익률7780TW Personal ProductsTW 시장7D2.5%0.6%5.1%1Y-22.6%-17.2%106.1%전체 주주 수익률 보기수익률 대 산업: 7780은 지난 1년 동안 -17.2%의 수익을 기록한 TW Personal Products 산업보다 저조한 성과를 냈습니다.수익률 대 시장: 7780은 지난 1년 동안 106.1%를 기록한 TW 시장보다 저조한 성과를 냈습니다.주가 변동성Is 7780's price volatile compared to industry and market?7780 volatility7780 Average Weekly Movement3.3%Personal Products Industry Average Movement4.1%Market Average Movement6.4%10% most volatile stocks in TW Market12.1%10% least volatile stocks in TW Market2.6%안정적인 주가: 7780는 지난 3개월 동안 TW 시장에 비해 주가 변동성이 크지 않았습니다.시간에 따른 변동성: 7780의 주간 변동성은 지난 1년간 10%에서 3%로 감소했습니다.회사 소개설립직원 수CEO웹사이트2018n/aTung-Ching Lincertifications.nutrasource.ca/certified-products/brand?id=DABI다이켄 바이오메디컬은 건강 식품의 연구 및 개발을 전문으로 하는 회사입니다. 이 회사는 대만 타이베이에 본사를 두고 있습니다. 다이켄 바이오메디컬은 선펀 인포(Sunfun Info Co., Ltd.)의 자회사입니다.더 보기Daiken Biomedical Co., Ltd. 기초 지표 요약Daiken Biomedical의 순이익과 매출은 시가총액과 어떻게 비교됩니까?7780 기초 통계시가총액NT$14.86b순이익 (TTM)NT$337.22m매출 (TTM)NT$2.02b44.1x주가수익비율(P/E)7.3x주가매출비율(P/S)7780는 고평가되어 있습니까?공정 가치 및 평가 분석 보기순이익 및 매출최근 실적 보고서(TTM)의 주요 수익성 지표7780 손익계산서 (TTM)매출NT$2.02b매출원가NT$762.71m총이익NT$1.26b기타 비용NT$924.23m순이익NT$337.22m최근 보고된 실적Mar 31, 2026다음 실적 발표일해당 없음주당순이익(EPS)0.42총이익률62.32%순이익률16.66%부채/자본 비율1.8%7780의 장기 실적은 어땠습니까?과거 실적 및 비교 보기배당3.8%현재 배당 수익률128%배당 성향7780는 안정적으로 배당을 지급합니까?7780 배당 기록 및 벤치마크 보기다가오는 배당을 받으려면 언제까지 7780를 매수해야 하나요?Daiken Biomedical 배당 일정배당락일Jun 22 2026배당 지급일Jul 08 2026배당락일까지 남은 일수13 days배당 지급일까지 남은 일수3 days7780는 안정적으로 배당을 지급합니까?7780 배당 기록 및 벤치마크 보기View Valuation기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/07/04 00:07종가2026/07/03 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Daiken Biomedical Co., Ltd.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
Upcoming Dividend • Jun 15Upcoming dividend of NT$0.89 per shareEligible shareholders must have bought the stock before 22 June 2026. Payment date: 08 July 2026. The company is paying out more than 100% of its earnings and cash flow. Trailing yield: 3.6%. Lower than top quartile of Taiwanese dividend payers (4.9%). Lower than average of industry peers (5.8%).
New Risk • May 09New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 40% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risks Dividend is not well covered by earnings and cash flows. Payout ratio: 115% Cash payout ratio: 191% High level of non-cash earnings (40% accrual ratio). Shareholders have been substantially diluted in the past year (35% increase in shares outstanding).
Buy Or Sell Opportunity • Mar 31Now 20% undervaluedOver the last 90 days, the stock has risen 11% to NT$20.00. The fair value is estimated to be NT$25.02, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 24% over the last 3 years. Earnings per share has declined by 14%.
Valuation Update With 7 Day Price Move • Mar 27Investor sentiment improves as stock rises 15%After last week's 15% share price gain to NT$22.00, the stock trades at a trailing P/E ratio of 52.7x. Average forward P/E is 19x in the Personal Products industry in Taiwan. Total returns to shareholders of 24% over the past year.
Buy Or Sell Opportunity • Mar 16Now 21% undervaluedOver the last 90 days, the stock has risen 20% to NT$19.30. The fair value is estimated to be NT$24.32, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 24% over the last 3 years. Earnings per share has declined by 13%.
New Risk • Mar 11New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 31% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (10% average weekly change). Dividend is not well covered by earnings and cash flows. Payout ratio: 218% Cash payout ratio: 122% High level of non-cash earnings (31% accrual ratio). Shareholders have been substantially diluted in the past year (35% increase in shares outstanding).
Upcoming Dividend • Jun 15Upcoming dividend of NT$0.89 per shareEligible shareholders must have bought the stock before 22 June 2026. Payment date: 08 July 2026. The company is paying out more than 100% of its earnings and cash flow. Trailing yield: 3.6%. Lower than top quartile of Taiwanese dividend payers (4.9%). Lower than average of industry peers (5.8%).
New Risk • May 09New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 40% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risks Dividend is not well covered by earnings and cash flows. Payout ratio: 115% Cash payout ratio: 191% High level of non-cash earnings (40% accrual ratio). Shareholders have been substantially diluted in the past year (35% increase in shares outstanding).
Buy Or Sell Opportunity • Mar 31Now 20% undervaluedOver the last 90 days, the stock has risen 11% to NT$20.00. The fair value is estimated to be NT$25.02, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 24% over the last 3 years. Earnings per share has declined by 14%.
Valuation Update With 7 Day Price Move • Mar 27Investor sentiment improves as stock rises 15%After last week's 15% share price gain to NT$22.00, the stock trades at a trailing P/E ratio of 52.7x. Average forward P/E is 19x in the Personal Products industry in Taiwan. Total returns to shareholders of 24% over the past year.
Buy Or Sell Opportunity • Mar 16Now 21% undervaluedOver the last 90 days, the stock has risen 20% to NT$19.30. The fair value is estimated to be NT$24.32, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 24% over the last 3 years. Earnings per share has declined by 13%.
New Risk • Mar 11New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 31% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (10% average weekly change). Dividend is not well covered by earnings and cash flows. Payout ratio: 218% Cash payout ratio: 122% High level of non-cash earnings (31% accrual ratio). Shareholders have been substantially diluted in the past year (35% increase in shares outstanding).
Reported Earnings • Mar 11Full year 2025 earnings released: EPS: NT$0.51 (vs NT$0.24 in FY 2024)Full year 2025 results: EPS: NT$0.51 (up from NT$0.24 in FY 2024). Revenue: NT$1.90b (up 39% from FY 2024). Net income: NT$337.9m (up 217% from FY 2024). Profit margin: 18% (up from 7.8% in FY 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 34% p.a. on average during the next 2 years, compared to a 9.4% growth forecast for the Personal Products industry in Asia.
공시 • Mar 10Daiken Biomedical Co., Ltd., Annual General Meeting, Jun 04, 2026Daiken Biomedical Co., Ltd., Annual General Meeting, Jun 04, 2026, at 09:00 Taipei Standard Time. Location: 4 floor building. a no,187, chin hua st., da-an district, taipei city Taiwan
Valuation Update With 7 Day Price Move • Mar 09Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to NT$20.40, the stock trades at a trailing P/E ratio of 61.5x. Average forward P/E is 19x in the Personal Products industry in Taiwan. Total returns to shareholders of 20% over the past year.
Buy Or Sell Opportunity • Jan 27Now 24% undervaluedOver the last 90 days, the stock has risen 56% to NT$26.05. The fair value is estimated to be NT$34.11, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 23% over the last 3 years. Earnings per share has declined by 20%.
Valuation Update With 7 Day Price Move • Jan 27Investor sentiment improves as stock rises 17%After last week's 17% share price gain to NT$26.05, the stock trades at a trailing P/E ratio of 78.6x. Average forward P/E is 22x in the Personal Products industry in Taiwan. Total returns to shareholders of 51% over the past year.
New Risk • Jan 16New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Dividend is not well covered by earnings and cash flows. Payout ratio: 218% Cash payout ratio: 112% Shareholders have been substantially diluted in the past year (35% increase in shares outstanding). Minor Risk Share price has been volatile over the past 3 months (6.5% average weekly change).
New Risk • Nov 26New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 35% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Dividend is not well covered by earnings and cash flows. Payout ratio: 218% Cash payout ratio: 152% Shareholders have been substantially diluted in the past year (35% increase in shares outstanding).
Upcoming Dividend • Nov 17Upcoming dividend of NT$1.70 per shareEligible shareholders must have bought the stock before 24 November 2025. Payment date: 30 December 2025. Payout ratio is a comfortable 75% and the cash payout ratio is 83%. Trailing yield: 2.2%. Lower than top quartile of Taiwanese dividend payers (5.4%). Lower than average of industry peers (5.6%).
Reported Earnings • Nov 08Third quarter 2025 earnings released: EPS: NT$1.06 (vs NT$0.80 in 3Q 2024)Third quarter 2025 results: EPS: NT$1.06 (up from NT$0.80 in 3Q 2024). Revenue: NT$449.3m (up 53% from 3Q 2024). Net income: NT$69.4m (up 45% from 3Q 2024). Profit margin: 16% (in line with 3Q 2024). Revenue is forecast to grow 34% p.a. on average during the next 3 years, compared to a 9.5% growth forecast for the Personal Products industry in Asia.
Buy Or Sell Opportunity • Oct 03Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 21% to NT$188. The fair value is estimated to be NT$239, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 32% over the last year. Earnings per share has declined by 9.8%.
Valuation Update With 7 Day Price Move • Sep 09Investor sentiment deteriorates as stock falls 28%After last week's 28% share price decline to NT$219, the stock trades at a trailing P/E ratio of 53.2x. Average trailing P/E is 17x in the Personal Products industry in Taiwan.
공시 • Aug 21Daiken Biomedical Co., Ltd. has filed a Follow-on Equity Offering.Daiken Biomedical Co., Ltd. has filed a Follow-on Equity Offering. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 6,615,000 Price\Range: TWD 158 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 1,512,000 Price(minimum): TWD 147.66
Upcoming Dividend • Aug 18Upcoming dividend of NT$2.45 per shareEligible shareholders must have bought the stock before 25 August 2025. Payment date: 15 September 2025. Payout ratio is on the higher end at 97%, and the cash payout ratio is above 100%. Trailing yield: 1.2%. Lower than top quartile of Taiwanese dividend payers (5.3%). Lower than average of industry peers (4.6%).
Reported Earnings • Aug 15Second quarter 2025 earnings released: EPS: NT$0.65 (vs NT$1.05 in 2Q 2024)Second quarter 2025 results: EPS: NT$0.65. Revenue: NT$454.9m (up 61% from 2Q 2024). Net income: NT$38.8m (up 13% from 2Q 2024). Profit margin: 8.5% (down from 12% in 2Q 2024). The decrease in margin was driven by higher expenses.
Valuation Update With 7 Day Price Move • Jul 16Investor sentiment improves as stock rises 39%After last week's 39% share price gain to NT$319, the stock trades at a trailing P/E ratio of 78.8x. Average trailing P/E is 17x in the Personal Products industry in Taiwan.
Upcoming Dividend • Jul 15Upcoming dividend of NT$2.19 per shareEligible shareholders must have bought the stock before 22 July 2025. Payment date: 15 August 2025. The company is paying out more than 100% of its earnings and cash flow. Trailing yield: 1.2%. Lower than top quartile of Taiwanese dividend payers (5.3%). Lower than average of industry peers (4.7%).
New Risk • Jul 09New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 7.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (42% accrual ratio). Minor Risk Share price has been volatile over the past 3 months (7.7% average weekly change).
Valuation Update With 7 Day Price Move • Jul 02Investor sentiment improves as stock rises 23%After last week's 23% share price gain to NT$221, the stock trades at a trailing P/E ratio of 54.7x. Average trailing P/E is 17x in the Personal Products industry in Taiwan.
Upcoming Dividend • Jun 10Upcoming dividend of NT$3.32 per shareEligible shareholders must have bought the stock before 17 June 2025. Payment date: 04 July 2025. The company is paying out more than 100% of its earnings and cash flow. Trailing yield: 2.3%. Lower than top quartile of Taiwanese dividend payers (5.2%). Lower than average of industry peers (5.2%).
Reported Earnings • Apr 25Full year 2024 earnings released: EPS: NT$2.43 (vs NT$10.32 in FY 2023)Full year 2024 results: EPS: NT$2.43 (down from NT$10.32 in FY 2023). Revenue: NT$1.36b (up 14% from FY 2023). Net income: NT$106.6m (down 34% from FY 2023). Profit margin: 7.8% (down from 14% in FY 2023). The decrease in margin was driven by higher expenses.
New Risk • Apr 14New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (25% accrual ratio). Minor Risk Latest financial reports are more than 6 months old (reported June 2024 fiscal period end).
공시 • Mar 08Daiken Biomedical Co., Ltd., Annual General Meeting, Jun 10, 2025Daiken Biomedical Co., Ltd., Annual General Meeting, Jun 10, 2025. Location: 4 floor building. a no,187, chin hua st., da-an district, taipei city Taiwan
